( 您好!臺灣時間:2023/02/06 11:20
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Ching-Fang Liu
論文名稱(外文):Expression and characterization of synuclein-related genes in zebrafish
指導教授:周志銘 老師
指導教授(外文):Chih-Ming Chou
外文關鍵詞:synucleinParkinson''''s diseasezebrafish
  • 被引用被引用:0
  • 點閱點閱:144
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
帕金森氏症(Parkinson''s disease, PD)是一種神經系統基底核黑質細胞退化性疾病,引起該疾病的可能原因可以大致區分成老化、環境因子及基因遺傳三大類,而在遺傳基因方面的研究已發現有十個以上的基因突變與該疾病的形成有關。其中α-synuclein是最早被發現的致病基因,然而相關的致病機轉目前仍未清楚。先前有研究指出所有的synuclein異構型在胚胎發育早期即在中樞神經系統被大量表現,顯示這一類基因對中樞神經系統的發育可能是很重要的,但是研究synuclein在胚胎早期發育方面的相關研究則較少。因此在本研究中將人類、老鼠以及斑馬魚synuclein相關基因選殖出來,以斑馬魚作為實驗動物模式,利用具有神經細胞專一性表現之啟動子經由顯微注射使其在斑馬魚的神經細胞中過量表現,分析這些基因在斑馬魚中樞神經系統早期發育過程中的基因表現特性,以期能更進一步的了解這些基因在神經系統中所具有的功能。實驗結果發現人類A30P突變型α-synuclein顯微注射組之螢光強度有隨著成長天數增加而明顯降低之現象,而正常型及A53T突變型α-synuclein則無此種現象。另外在本實驗中觀察人類正常型α-synuclein於斑馬魚神經系統內表現情形,發現正常型α-synuclein重組質體在神經元纖維的表現情形,呈現密集而不連續性的點狀分布,而該現象在人類A30P與A53T突變型α-synuclein則僅各有37%及58%的發生率。此研究結果提供我們未來在研究該基因的致病機轉以及基因突變後所造成之蛋白質特性改變等兩方面一些新的研究方向。
Parkinson''s disease (PD) is a neurodegenerative motor disorder that is characterized by the loss of dopaminergic neurons from the substantia nigra. The pathological mechanism of Parkinson’s disease is categorized in aging, environmental factor, and genetic disorders. In genetic research, there were more than 10 genes mutations identified in this disease. The first pathogenetic gene identified is α-synuclein, but its phathological mechanism is unknown. In previous study, it’s demonstrated that all synuclein isoforms expressed massively in early embryologic development of the central nervous system. These results revealed that synuclein may be essential to neurogenesis. In our research, we cloned synuclein of human, rat, and zebrafish. Using constructs containing synuclein and green fluorescent protein (GFP) genes drived by the neural-specific promoter, HuC, over-expressed in zebrafish neural system. In our study, it’s demonstrated that the intensity of fluorescence in human α-synuclein containing the A30P Parkinson''s disease mutation injected embryos decreased along with the growing days obviously, however, the same phenomenon was not found in human α-synuclein wild type and human α-synuclein containing the A53T Parkinson''s disease mutation injected embryos. Furthermore, we found that the expression of human α-synuclein wild type occurred dense and discrete dots in neurite, but the pattern found at the incidence of 37 % and 58 % in α-synuclein mutant A30P and A53T respectively. These results provided us some new directions in researches about the possible pathogenesis of PD and the property change in α-synuclein Parkinson''s disease mutation in the future.
施瑔芳 (1994). 魚類生理學,中國農業出版社。
Antic, D. and Keene, J. D. (1997). Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and
posttranscriptional gene expression. Am J Hum Genet 61, 273-8.
Barami, K., Iversen, K., Furneaux, H. and Goldman, S. A. (1995). Hu protein as an early marker of neuronal phenotypic differentiation by subependymal zone cells of the adult songbird forebrain. J Neurobiol 28, 82-101.
Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N. and Mouradian, M. M. (1999). Degradation of alpha-synuclein by proteasome. J Biol Chem 274, 33855-8.
Chan, P., Jiang, X., Forno, L. S., Di Monte, D. A., Tanner, C. M. and Langston, J. W. (1998a). Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson''s disease. Neurology 50, 1136-7.
Chan, P., Tanner, C. M., Jiang, X. and Langston, J. W. (1998b). Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson''s disease. Neurology 50, 513-4.
Chung, C. T., Niemela, S. L. and Miller, R. H. (1989). One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci U S A 86, 2172-5.
Clayton, D. F. and George, J. M. (1999). Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58, 120-9.
Conway, K. A., Harper, J. D. and Lansbury, P. T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4, 1318-20.
Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Harper, J. D., Williamson, R. E. and Lansbury, P. T., Jr. (2000a). Accelerated oligomerization by Parkinson''s disease linked alpha-synuclein mutants. Ann N Y Acad Sci 920, 42-5.
Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E. and Lansbury, P. T., Jr. (2000b). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson''s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97, 571-6.
Davidson, W. S., Jonas, A., Clayton, D. F. and George, J. M. (1998). Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273, 9443-9.
Dennis J. Cordato, Daniel K.Y. Chan (2004). Genetics and Parkinson’s disease. J Clin Neurosci 11, 119-23.
Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L. and van der Putten, H. (2003). Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 14-44.
Duda, J. E., Lee, V. M. and Trojanowski, J. Q. (2000). Neuropathology of synuclein aggregates. J Neurosci Res 61, 121-7.
Duyckaerts, C. and Hauw, J. J. (2003). Lewy bodies, a misleading marker for Parkinson''s disease ?. Bull Acad Natl Med 187, 277-92; discussion 292-3.
Farrer, M., Wavrant-De Vrieze, F., Crook, R., Boles, L., Perez-Tur, J., Hardy, J., Johnson, W. G., Steele, J., Maraganore, D., Gwinn, K. and Lynch, T. (1998). Low frequency of alpha-synuclein mutations in familial Parkinson''s disease. Ann Neurol 43, 394-7.
Forno, L. S. (1996). Neuropathology of Parkinson''s disease. J Neuropathol Exp Neurol 55, 259-72.
Gasser, T., Muller-Myhsok, B., Wszolek, Z. K., Oehlmann, R., Calne, D. B., Bonifati, V., Bereznai, B., Fabrizio, E., Vieregge, P. and Horstmann, R. D. (1998). A susceptibility locus for Parkinson''s disease maps to chromosome 2p13. Nat Genet 18, 262-5.
George, J. M., Jin, H., Woods, W. S. and Clayton, D. F. (1995). Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-72.
Gispert, S., Del Turco, D., Garrett, L., Chen, A., Bernard, D. J., Hamm-Clement, J., Korf, H. W., Deller, T., Braak, H., Auburger, G. and Nussbaum, R. L. (2003). Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24, 419-29.
Hashimoto, M., Bar-On, P., Ho, G., Takenouchi, T., Rockenstein, E., Crews, L. and Masliah, E. (2004). Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson''s disease. J Biol Chem 279, 23622-9.
Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. and Masliah, E. (2001). beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-23.
Hashimoto, M., Rockenstein, E. and Masliah, E. (2003). Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci 991, 171-88.
Hashimoto, M., Yoshimoto, M., Sisk, A., Hsu, L. J., Sundsmo, M., Kittel, A., Saitoh, T., Miller, A. and Masliah, E. (1997). NACP, a synaptic protein involved in Alzheimer''s disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237, 611-6.
Heintz, N. and Zoghbi, H. (1997). alpha-Synuclein--a link between Parkinson and Alzheimer diseases? Nat Genet 16, 325-7.
Hjorth, J. and Key, B. (2002). Development of axon pathways in the zebrafish central nervous system. Int J Dev Biol 46, 609-19.
Hsu, L. J., Mallory, M., Xia, Y., Veinbergs, I., Hashimoto, M., Yoshimoto, M., Thal, L. J., Saitoh, T. and Masliah, E. (1998). Expression pattern of synucleins (non-Abeta component of Alzheimer''s disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 71, 338-44.
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A. and Saitoh, T. (1995). The precursor protein of non-A beta component of Alzheimer''s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-75.
Jakes, R., Spillantini, M. G. and Goedert, M. (1994). Identification of two distinct synucleins from human brain. FEBS Lett 345, 27-32.
Jenco, J. M., Rawlingson, A., Daniels, B. and Morris, A. J. (1998). Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 4901-9.
Jenner, P. (2001). Parkinson''s disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24, 245-7.
Jensen, P. H., Hojrup, P., Hager, H., Nielsen, M. S., Jacobsen, L., Olesen, O. F., Gliemann, J. and Jakes, R. (1997). Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 323 ( Pt 2), 539-46.
Kholodilov, N. G., Neystat, M., Oo, T. F., Lo, S. E., Larsen, K. E., Sulzer, D. and Burke, R. E. (1999). Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem 73, 2586-99.
Kim, C. H., Ueshima, E., Muraoka, O., Tanaka, H., Yeo, S. Y., Huh, T. L. and Miki, N. (1996). Zebrafish elav/HuC homologue as a very early neuronal marker. Neurosci Lett 216, 109-12.
Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. and Schilling, T. F. (1995). Stages of embryonic development of the zebrafish. Dev Dyn 203, 253-310.
Klein, S. L., Strausberg, R. L., Wagner, L., Pontius, J., Clifton, S. W. and Richardson, P. (2002). Genetic and genomic tools for Xenopus research: The NIH Xenopus initiative. Dev Dyn 225, 384-91.
Kobayashi, M., Nishikawa, K. and Yamamoto, M. (2001). Hematopoietic regulatory domain of gata1 gene is positively regulated by GATA1 protein in zebrafish embryos. Development 128, 2341-50.
Kolata, G. (1983). Monkey model of Parkinson''s disease. Science 220, 705.
Kosaka, K. (1990). Diffuse Lewy body disease in Japan. J Neurol 237, 197-204.
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L. and Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson''s disease. Nat Genet 18, 106-8.
Langston, J. W. and Ballard, P. A., Jr. (1983). Parkinson''s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309, 310.
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T. and Lansbury, P. T., Jr. (2002). Alpha-synuclein, especially the Parkinson''s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-102.
Li, J., Uversky, V. N. and Fink, A. L. (2001). Effect of familial Parkinson''s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-13.
Lin, J. J., Yueh, K. C., Chang, D. C. and Lin, S. Z. (1999). Absence of G209A and G88C mutations in the alpha-synuclein gene of Parkinson''s disease in a Chinese population. Eur Neurol 42, 217-20.
Link, C. D. (2001a). Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev 122, 1639-49.
Link, C. D., Johnson, C. J., Fonte, V., Paupard, M., Hall, D. H., Styren, S., Mathis, C. A. and Klunk, W. E. (2001b). Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22, 217-26.
Liu, D. W. and Westerfield, M. (1990). The formation of terminal fields in the absence of competitive interactions among primary motoneurons in the zebrafish. J Neurosci 10, 3947-59.
Maraganore, D. M., Harding, A. E. and Marsden, C. D. (1991). A clinical and genetic study of familial Parkinson''s disease. Mov Disord 6, 205-11.
Maries, E., Dass, B., Collier, T. J., Kordower, J. H. and Steece-Collier, K. (2003). The role of alpha-synuclein in Parkinson''s disease: insights from animal models. Nat Rev Neurosci 4, 727-38.
Markopoulou, K., Wszolek, Z. K., Pfeiffer, R. F. and Chase, B. A. (1999). Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann Neurol 46, 374-81.
Maroteaux, L. and Scheller, R. H. (1991). The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 11, 335-43.
Maroteaux, L., Campanelli, J. T. and Scheller, R. H. (1988). Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8, 2804-15.
Marusich, M. F., Furneaux, H. M., Henion, P. D. and Weston, J. A. (1994). Hu neuronal proteins are expressed in proliferating neurogenic cells. J Neurobiol 25, 143-55.
McLean, P. J., Kawamata, H., Ribich, S. and Hyman, B. T. (2000). Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson''s disease-linked mutations. J Biol Chem 275, 8812-6.
Meng, A., Tang, H., Ong, B. A., Farrell, M. J. and Lin, S. (1997). Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl Acad Sci U S A 94, 6267-72.
Mullis, K. B. and Faloona, F. A. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155, 335-50.
Okano, H. J. and Darnell, R. B. (1997). A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci 17, 3024-37.
Ozawa, T., Takano, H., Onodera, O., Kobayashi, H., Ikeuchi, T., Koide, R., Okuizumi, K., Shimohata, T., Wakabayashi, K., Takahashi, H. and Tsuji, S. (1999). No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 270, 110-2.
Paik, S. R., Lee, J. H., Kim, D. H., Chang, C. S. and Kim, Y. S. (1998). Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer''s disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett 421, 73-6.
Park, H. C., Kim, C. H., Bae, Y. K., Yeo, S. Y., Kim, S. H., Hong, S. K., Shin, J., Yoo, K. W., Hibi, M., Hirano, T., Miki, N., Chitnis, A. B. and Huh, T. L. (2000). Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev Biol 227, 279-93.
Peters, K. G., Rao, P. S., Bell, B. S. and Kindman, L. A. (1995). Green fluorescent fusion proteins: powerful tools for monitoring protein expression in live zebrafish embryos. Dev Biol 171, 252-7.
Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., Lazzarini, A. M., Nussbaum, R. L. and Duvoisin, R. C. (1996). Mapping of a gene for Parkinson''s disease to chromosome 4q21-q23. Science 274, 1197-9.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I. and Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson''s disease. Science 276, 2045-7.
Rochet, J. C., Conway, K. A. and Lansbury, P. T., Jr. (2000). Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10619-26.
Samii, A., Markopoulou, K., Wszolek, Z. K., Sossi, V., Dobko, T., Mak, E., Calne, D. B. and Stoessl, A. J. (1999). PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 53, 2097-102.
Schagger, H. and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166, 368-79.
Shulman, J. M., Shulman, L. M., Weiner, W. J. and Feany, M. B. (2003). From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol 16, 443-9.
Spillantini, M. G., Divane, A. and Goedert, M. (1995). Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 27, 379-81.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-40.
Surguchov, A., Palazzo, R. E. and Surgucheva, I. (2001). Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskeleton 49, 218-28.
Szabo, A., Dalmau, J., Manley, G., Rosenfeld, M., Wong, E., Henson, J., Posner, J. B. and Furneaux, H. M. (1991). HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 67, 325-33.
Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L. and Masliah, E. (1998). Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 152, 367-72.
Tanaka, Y., Engelender, S., Igarashi, S., Rao, R. K., Wanner, T., Tanzi, R. E., Sawa, A., V, L. D., Dawson, T. M. and Ross, C. A. (2001). Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10, 919-26.
Tiunova, A. A., Anokhin, K. V., Saha, A. R., Schmidt, O., Hanger, D. P., Anderton, B. H., Davies, A. M., Ninkina, N. N. and Buchman, V. L. (2000). Chicken synucleins: cloning and expression in the developing embryo. Mech Dev 99, 195-8.
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y. and Saitoh, T. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90, 11282-6.
Vaughan, J. R., Durr, A., Tassin, J., Bereznai, B., Gasser, T., Bonifati, V., De Michele, G., Fabrizio, E., Volpe, G., Bandmann, O., Johnson, W. G., Golbe, L. I., Breteler, M., Meco, G., Agid, Y., Brice, A., Marsden, C. D. and Wood, N. W. (1998a). The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson''s disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson''s Disease. Ann Neurol 44, 270-3.
Vaughan, J. R., Farrer, M. J., Wszolek, Z. K., Gasser, T., Durr, A., Agid, Y., Bonifati, V., DeMichele, G., Volpe, G., Lincoln, S., Breteler, M., Meco, G., Brice, A., Marsden, C. D., Hardy, J. and Wood, N. W. (1998b). Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson''s disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson''s Disease (GSPD). Hum Mol Genet 7, 751-3.
Wakabayashi, K., Yoshimoto, M., Tsuji, S. and Takahashi, H. (1998). Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249, 180-2.
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. and Rubinsztein, D. C. (2003). Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278, 25009-13.
Westerfield, M. (1995). The Zebrafish Book. 3rd edn. Eugene, OR: University of Oregon Press.
Yao, K. M., Samson, M. L., Reeves, R. and White, K. (1993). Gene elav of Drosophila melanogaster: a prototype for neuronal-specific RNA binding protein gene family that is conserved in flies and humans. J Neurobiol 24, 723-39.
Zhao, K. N., Tomlinson, L., Liu, W. J., Gu, W. and Frazer, I. H. (2003). Effects of additional sequences directly downstream from the AUG on the expression of GFP gene. Biochim Biophys Acta 1630, 84-95.
第一頁 上一頁 下一頁 最後一頁 top